Примери за използване на Ritonavir twice на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Mg PREZISTA/60 mg ritonavir twice daily.
The recommended dose is 700 mg fosamprenavir twice daily with 100 mg ritonavir twice daily.
Milligram darunavir+ 60 milligram ritonavir twice a day more than 40 kilograms*.
The recommended dose of Invirase and ritonavir is 1000 mg Invirase plus 100 mg ritonavir twice daily.
Cells/ mm3: lopinavir/ ritonavir twice daily.
The recommended dose of Invirase and ritonavir is 1000 mg Invirase plus 100 mg ritonavir twice daily.
Milligram darunavir+ 50 milligram ritonavir twice a day between 30 and 40 kilograms.
Adults The recommended dose is one 700 mg Telzir tablet twice daily with 100 mg ritonavir twice daily.
A boosted dose of 800 mg indinavir/100 mg ritonavir twice daily results in increased risk of adverse events.
In 2003, the FDA approved dosing of Invirase at 1,000 mg plus100 mg of ritonavir twice a day.
FPV/ RTV BID- Fosamprenavir with ritonavir twice daily, LPV/ RTV BID- Lopinavir/ ritonavir twice daily.
Milligram PREZISTA together with 100 milligram ritonavir twice daily. OR.
These patients received darunavir/ritonavir twice daily in combination with other antiretroviral agents(see section 4.2 for dosage recommendations per body weight).
If you are taking lopinavir/ritonavir twice a day.
Milligram PREZISTA(2 tablets containing 300 milligram of PREZISTA or 1 tablet containing 600 milligram of PREZISTA)together with 100 milligram ritonavir twice daily.
Kaletra co-administered with an additional 100 mg ritonavir twice daily resulted in an increase of lopinavir AUC and Cmin of 33% and 64%, respectively, as compared to Kaletra alone.
Milligram darunavir+ 100 milligram ritonavir twice a day.
In the presence of 400/100 mg lopinavir/ritonavir twice daily, a strong CYP3A4 inhibitor, exposure to selexipag increased approximately 2-fold, whereas the exposure to the active metabolite of selexipag did not change.
Mg(3.8 ml) PREZISTA/50 mg(0.6 ml) ritonavir twice daily.
Multiple dosing with 400/100 mg lopinavir/ritonavir twice daily for 2 weeks and without meal restriction produced a mean± SD lopinavir peak plasma concentration(Cmax) of 12.3± 5.4 μg/ml, occurring approximately 4 hours after administration.
Mg(two 250 mg capsules) Aptivus together with- 200 mg(two 100 mg capsules) ritonavir twice per day with food.
One dose is between 15 and 30 kilograms 375 milligram PREZISTA+ 50 milligram ritonavir twice a day between 30 and 40 kilograms 450 milligram PREZISTA+ 60 milligram ritonavir twice a day more than 40 kilograms*.
Milligram Darunavir Krka(1 tablet containing 600 milligram of Darunavir Krka)together with 100 milligram ritonavir twice daily.
The median durations of prior exposure to NRTIs were 257 weeks for patients receiving fosamprenavir with ritonavir twice daily(79% had≥ 3 prior NRTIs) and 210 weeks for patients receiving lopinavir/ritonavir(64% had≥ 3 prior NRTIs).
For patients already taking HIV medicines,the recommended dose of Invirase is 1,000 mg with 100 mg ritonavir twice daily.
When considering the proportion of patients with undetectable viral load in the fosamprenavir with ritonavir twice daily dosing regimens and lopinavir/ ritonavir arms respectively, results showed a trend in favour of the lopinavir/ ritonavir arms.
OR- 600 milligram darunavir(2 tablets containing 300 milligram of darunavir or 1 tablet containing 600 milligram of darunavir)together with 100 milligram ritonavir twice daily.
Efficacy of darunavir 600 mg twice daily co-administered with 100 mg ritonavir twice daily in ARTexperienced patients.
In order toachieve effective tipranavir plasma concentrations and a twice daily dosing regimen, coadministration of tipranavir with low dose ritonavir twice daily is essential(see section 4.2).
At steady state,lopinavir protein binding remains constant over the range of observed concentrations after 400/100 mg lopinavir/ritonavir twice daily, and is similar between healthy volunteers and HIV-positive patients.